News: Latest News
Code Biotherapeutics Names Alex S. Tracy, PhD, as Chief Technical Officer
- Dr. Tracy joins growing leadership team to advance development of 3DNA® Platform and product pipeline
- Brings more than 20 years of scientific and technical expertise in process and analytic development, manufacturing, quality, and CMC regulatory in gene therapy, biologics, vaccines, and novel therapies
Greater Philadelphia, Pa., November 14, 2022 – Code Biotherapeutics, Inc. (Code Bio), a biotechnology company pioneering the targeted delivery of precision genetic medicines, today announces the appointment of Alex Tracy, PhD, as Chief Technical Officer.
“I am thrilled to welcome Alex to the team,” said Brian P. McVeigh, Code Bio Co-Founder, Chairman, and Chief Executive Officer. “Alex is a seasoned leader with extensive experience building teams and executing CMC strategy for novel platforms. His contributions will have a significant impact on the evolution of our manufacturing strategy and technical operations and be a key enabler to the delivery of our mission to treat the untreatable and cure the incurable.”
Dr. Tracy will be responsible for developing Code Bio’s overall technical and manufacturing strategy, as well as building and leading a team to manage all stages of manufacturing, quality control, supply chain and CMC facilities management. He will also play an integral role in delivering Code Bio’s proprietary, innovative, non-viral gene delivery technology and product pipeline.
Dr. Tracy joins Code Bio from BridgeBio Gene Therapy where he served as Chief Technical Officer, directing process and analytical development, and external manufacturing for several clinical-stage adeno-associated virus (AAV) gene therapy programs. Prior to his role at BridgeBio Gene Therapy, Dr. Tracy led the technical, Regulatory and QA organizations at Istari Oncology and developed the late-stage manufacturing strategy that was approved by the FDA for Istari’s oncolytic virus program.
“I am excited about the opportunity to join Code Bio, and to work side by side with a growing team committed to addressing the current challenges of delivering genetic medicines,” said Alex Tracy, PhD. “I am looking forward to playing a key role in delivering the novel, proprietary 3DNA technology that has the potential to be transformative.”
Beyond his experience with BridgeBio Gene Therapy and Istari Oncology, Dr. Tracy held the role of Vice President of Pharmaceutical Development and Manufacturing at Enzyvant/Roivant Sciences, Head of Manufacturing Science & Technology at Hospira, a Pfizer Company, as well as Global Head of Manufacturing Science & Technology at Novartis Vaccines & Diagnostics.
Dr. Tracy received a PhD in Biochemistry and Molecular Biology from University of Georgia, an M.S. in Chemistry at George Mason University, as well as a B.S. in Chemistry and English from The College of William and Mary.
About Code Bio therapeutics, Inc.
Headquartered in Greater Philadelphia, Code Bio is a biotechnology company pioneering the development of genetic medicines to treat and potentially cure serious and life-threatening genetic diseases. By leveraging its proprietary, novel, multivalent, precision genetic medicine delivery platform, 3DNA®, Code Bio’s approach can overcome many of the challenges and liabilities currently plaguing traditional genetic medicine delivery approaches such as immunogenicity, limitations on genetic payload size, dose related toxicities, and suboptimal bioavailability. The company is advancing an internal pipeline of therapies focused on serious and life-threatening diseases while also developing multiple collaborative partnerships to take forward additional programs in both rare and prevalent diseases. For more information, visit www.codebiotx.com.
Code Bio Media Contact:
Sam Brown Inc. Healthcare Communications